Amylin, AIG: After-Hours Trading
The company has yet to determine how many additional shares it plans to issue or at what price but by increasing the amount of outstanding stock, the holdings of existing shareholders will be correspondingly diluted.
In a regulatory filing, Amylin said it plans to use the proceeds of the offering for the "commercialization of BYDUREON, as well as for general corporate purposes which may include research and development expenses, capital expenditures, working capital and general administrative expenses."
The stock was last quoted at $15.41, down 4.7%, on volume of 232,000, according to Nasdaq.com. Based on Wednesday's regular-session close at $16.17, Amylin shares have soared 40% since the start of 2012, hitting a 52-week high of $18.45 on Feb. 17.The company received approval of Bydureon, a weekly treatment for type 2 diabetes, on Jan. 27, and the drug became available by prescription in the United States on Feb. 13. Check out TheStreet's quote page for Amylin for year-to-date share performance, analyst ratings, earnings estimates and much more.
AIGShares of insurance giant American International Group (AIG) ticked lower in extended trades following news that the U.S. Treasury is selling $6 billion worth of its bailout-related holdings in the company. The stock was last quoted at $29, down 1.5%, on volume of more than 3.4 million, according to Nasdaq.com. AIG itself is expected to purchase up to $3 billion worth of the stock being sold by the Treasury, which will still have nearly $42 billion sunk into the company following its 2008 bailout. AIG shares are up more than 25% year-to-date. Check out TheStreet's quote page for AIG for year-to-date share performance, analyst ratings, earnings estimates and much more.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV